Research programme: chitinase inhibitors - OncoArendi Therapeutics

Drug Profile

Research programme: chitinase inhibitors - OncoArendi Therapeutics

Alternative Names: AMCase inhibitors – OncoArendi Therapeutics; Chitotriosidase inhibitors - OncoArendi Therapeutics; OAT 889; OATD 01

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yale University
  • Developer OncoArendi Therapeutics
  • Class Antiasthmatics; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Acidic mammalian chitinase inhibitors; Chitinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 09 Oct 2017 OncoArendi Therapeutics receives approval from German Federal Institute for Drugs and Medical Devices (BfArM) for initiation of a phase I trial of OATD 01 in Asthma (In volunteers)
  • 09 Oct 2017 OncoArendi Therapeutics plans a multiple-ascending dose clinical trial of OATD-01 in 2018
  • 09 Sep 2017 Preclinical trials in Chronic obstructive pulmonary disease in Poland (PO) before September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top